Take this for what it is worth. I left the company because the management team is a mess. No vision or leadership. The endosheath is not what they had hoped. It is viewed in the majority of accounts as an added expense. It is a solution to a problem that does not exist. It is a very difficult sale in many territories. Does it have its place in certain accounts, yes. If I were having a cysto would I want it used, yes. However, practices can not offer it to everyone and take the $35-$40 hit on every cysto. The companies ROI was extremely flawed. As for UPC, again the company has no vision. The buy and bill model is dying. Many offices just can't justify tying up a room for 45 minutes to make $45-$70 per visit. In addition, something management never understood is that there is a maximum number of patients a practice can have on PTNS before they run out of time slots. They always push for more boxes, well some accounts are at max and can't order more boxes. The question you ask about Medtronic is the big question for the last year. Will they undercut the price? Will they bundle with interstim? Will they go after key accounts? Who knows, but we do know that Medtronic is a huge company with deep pockets and Cogentix is a small company burning through cash. A small hit to business revenue with eventually bankrupt the company.
My advice to you. If you are desperate and need a job, take it. You can make some money in the right territory. If you have a decent job and think this is a stepping stone. Stay where you are.
